Share on StockTwits

Analysts at Oppenheimer cut their target price on shares of Opko Health (NYSE:OPK) from $13.00 to $12.00 in a research report issued to clients and investors on Monday, American Banking News.com reports. The firm currently has an “outperform” rating on the stock. Oppenheimer’s price target indicates a potential upside of 46.70% from the stock’s previous close.

Shares of Opko Health (NYSE:OPK) traded down 1.80% on Monday, hitting $8.18. 1,507,780 shares of the company’s stock traded hands. Opko Health has a 52-week low of $6.14 and a 52-week high of $12.95. The stock has a 50-day moving average of $8.63 and a 200-day moving average of $9.09. The company’s market cap is $3.317 billion. Opko Health also saw a significant growth in short interest in the month of April. As of April 30th, there was short interest totalling 50,337,366 shares, a growth of 6.2% from the April 15th total of 47,379,151 shares. Currently, 23.4% of the shares of the company are sold short. Based on an average daily volume of 2,431,204 shares, the short-interest ratio is currently 20.7 days.

Opko Health (NYSE:OPK) last issued its quarterly earnings data on Friday, May 9th. The company reported ($0.11) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.10) by $0.01. The company had revenue of $22.30 million for the quarter, compared to the consensus estimate of $22.77 million. On average, analysts predict that Opko Health will post $-0.36 earnings per share for the current fiscal year.

In other Opko Health news, CEO Phillip Md Et Al Frost bought 20,400 shares of the company’s stock in a transaction that occurred on Tuesday, May 13th. The shares were purchased at an average cost of $8.35 per share, with a total value of $170,340.00. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Separately, analysts at Ned Davis Research upgraded shares of Opko Health from a “sell” rating to a “neutral” rating in a research note on Monday, April 28th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $12.50.

OPKO Health, Inc (NYSE:OPK) is a multi-national biopharmaceutical and diagnostics company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.